EDITORIAL The Growing Burden of Pulmonary Hypertension in the Modern Era A Zebra No More? See Article by Wijeratne et al. Stephen C. Mathai, MD, MHS John J. Ryan, MD ulmonary hypertension (PH) is a heterogeneous syndrome characterized by elevated pulmonary pressures. Although often suspected based on symp- P toms of dyspnea and elevated estimates of pulmonary arterial systolic pres- sures on echocardiogram, PH can only be diagnosed by right heart catheterization demonstrating a mean pulmonary artery pressure ≥25 mm Hg. Clinically, PH can result from various comorbid conditions, including underlying cardiac, pulmonary, thromboembolic, and miscellaneous diseases. PH in the absence of these comorbid conditions constitutes a small subset of PH, known as pulmonary arterial hyperten- sion (PAH). Over the last several years, determining the incidence and prevalence of PH in population-based studies has proven challenging, in part, because of the lack of specificity of diagnosis codes commonly used in reimbursement system data- bases. These codes do not align with the current classification system and thus are unable to accurately distinguish disease phenotypes. In addition, proper clas- sification of PH, according to guideline recommendations, requires not only a high clinical suspicion but also extensive targeted testing, which is often
Circulation: Cardiovascular Quality & Outcomes – Wolters Kluwer Health
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud